TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores

Transcatheter Aortic Valve Replacement Clinical Trial

Official title:

TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04517955
• Other study ID #: 088891/2019
• Status: Recruiting
• Start date: July 1, 2020
• Est. completion date: March 30, 2025

Study information

• Verified date: August 2020
• Source: University of Athens
• Contact: Dimitris Tousoulis, Prof
• Phone: +302132088099
• Email: tousoulis[@]med.uoa.gr
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Single arm, observational trial of Transcatheter Aortic Valve Implantation (TAVI) with the Medtronic Evolut R and Evolut Pro The primary objective of this trial is to evaluate device success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk.

Description:

The purpose of this study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in septuagenarians with severe, symptomatic Aortic Stenosis (AS) and risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk.

The primary objective of this trial is to evaluate device success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk.

The secondary objective is to assess early safety (at 30 days) and clinical efficacy (after 30 days) of the TAVI procedure.

Exploratory objective: comparative health economics in septuagenarians with symptomatic severe aortic stenosis and intermediate surgical risk treated with Transcatheter Aortic Valve Implantation (TAVI) vs Surgical Aortic Valve Replacement (SAVR) (matched historic cohort)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: March 30, 2025
• Est. primary completion date: September 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 75-79

2. Subject must have Society of Thoracic Surgeons (STS) score >=4% and <=8%

3. Subject must have at least one from the risk factors presented below:

i. Severely atherosclerotic or porcelain aorta ii. Internal Mammary Artery (IMA) or other conduit(s) crossing midline and/or adherent to posterior table of sternum iii. Pre-existing mechanical valve in any other position iv. Severe right ventricular dysfunction v. Hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis or other skeletal abnormalities, evidence of severe radiation damage, history of multiple recurrent pleural effusions causing internal adhesions) vi. Severe liver disease/cirrhosis vii. Frailty viii. Malignancy with life expectancy that exceeds 24 months ix. Renal replacement therapy with creatinine levels >200mmol/L or 2.26 mg/dl

4. Heart team consisting of at least one interventional cardiologist and one cardiac surgeon agree on indication and treatment proposal, based on their clinical judgment (including anatomy assessment, risk factors, etc)

5. Critical aortic valve area defined as an initial aortic valve area of <=1cm2 or aortic valve index <0.6cm2/m2

6. In presence of normal left ventricular function:

1. Mean gradient >40mmHg OR Vmax>4m/sec OR

2. In presence of low flow, low gradient severe AS, a dobutamine stress echo must be conducted that demonstrates presence of contractile reserve defined as follows >=20% increase in stroke volume and mean gradient >40mmHg

7. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater

8. The subject is suitable for direct TAVI not preceded by balloon valvuloplasty according to the judgment of the treating physicians

9. The subject and the treating physician agree that the subject will return for all required post procedure follow-up visits.

Exclusion Criteria:

1. Hypersensitivity or contraindication to aspirin, heparin, clopidogrel, coumadin, nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated;

2. Blood dyscrasias as defined: leukopenia (WBC<1000/mm3), thrombocytopenia (platelet count <50.000cells/mm3), history of bleeding diathesis or coagulopathy;

3. Ongoing sepsis, including active endocarditis

4. Any condition considered a contraindication to extracorporeal assistance;

5. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within six weeks prior treatment

6. Cardiogenic shock manifested by low cardiac output, vasopressor dependence or mechanical hemodynamic support;

7. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA)

8. Active gastrointestinal (GI) bleeding within the past 3 months

9. Subject refuses a blood transfusion;

10. Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits);

11. Multivessel coronary artery disease with a Syntax score >22

12. Estimated life expectancy of less than 24 months due to associated non-cardiac comorbid conditions

13. Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consentor adherence to the protocol required follow-up exams;

14. Currently participating in an investigational drug or another device trial (excluding registries)

15. Evidence of an acute myocardial infarction <=30 days before the index procedure

16. Need for emergency surgery for any reason

17. Uncontrolled atrial fibrillation

Anatomical Exclusion Criteria:

18. Native aortic annulus size <18mm or >30mm per the baseline diagnostic imaging;

19. Mixed aortic valve disease [aortic stenosis and aortic regurgitation with predominant aortic regurgitation (3-4+]

20. Severe mitral or severe tricuspid regurgitation

21. Severe mitral stenosis;

22. Hypertrophic obstructive cardiomyopathy

23. Echocardiographic or Multislice Computed Tomography (MSCT) evidence of intracardiac mass, thrombus or vegetation

24. Anatomy of the aortic root and ascending aorta not suitable for TAVI with Evolut R or Evolut Pro system (aortic root angulation >70 degrees for femoral and left subclavian access or >30 degrees for right subclavian access)

25. Congenital bicuspid or unicuspid valve verified by echocardiography Vascular Exclusion Criteria

26. Transarterial access not able to accommodate an 16 French sheath

Related Conditions & MeSH terms

• Transcatheter Aortic Valve Replacement

Intervention

Device:
• Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro

Locations

Country	Name	City	State
Greece	Cardiology Department, Hippokration Hospital	Athens
Greece	First Department of Cardiology, National & Kapodistrian University of Athens	Athens
Greece	Onassis Cardiac Surgery Center	Athens
Greece	University Hospital of Heraklion	Heraklion
Greece	University Hospital of Ioannina	Ioannina

Sponsors (1)

Lead Sponsor	Collaborator
University of Athens

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Device success (VARC-2 criteria)	Absence of procedural mortality; Correct positioning of the prosthetic heart valve into the proper anatomical location; Intended performance of the prosthetic heart valve (mean aortic valve gradient<20mmHg or peak velocity < 3m/s, and no moderate or severe prosthetic valve regurgitation) as assessed with 24h post implantation and pre-discharge echocardiogram	30 days
Secondary	Rate of All-cause mortality	Early Safety	30 days
Secondary	Rate of All stroke (disabling and non-disabling)	Early Safety	30 days
Secondary	Rate of Life-threatening bleeding	Early Safety	30 days
Secondary	Rate of Acute Kidney Injury-Stage 2 or 3 (including renal replacement therapy)	Early Safety	30 days
Secondary	Rate of Coronary artery obstruction requiring intervention	Early Safety	30 days
Secondary	Rate of Major vascular complication	Early Safety	30 days
Secondary	Rate of Valve-related dysfunction requiring repeat procedure (BAV, TAVI or SAVR)	Early Safety	30 days
Secondary	Rate of New pacemaker implantation	Early Safety	30 days
Secondary	Rate of All-cause mortality	Clinical Efficacy	after 30 days and up to 2 years
Secondary	Rate of All stroke (disabling and non-disabling)	Clinical Efficacy	after 30 days and up to 2 years
Secondary	Rate of Hospitalizations for valve-related symptoms or worsening congestive heart failure NYHA class III or IV	Clinical Efficacy	after 30 days and up to 2 years
Secondary	Rate of Valve related dysfunction	Mean aortic valve gradient >=20mmHg, Effective orifice area (EOA)<=0.9-1.1cm2, and/or Dimensionless Valve Index (DVI)<0.35 m/s and/or moderate or severe prosthetic valve regurgitation	after 30 days and up to 2 years